Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference

Journal of Immunological Methods

Volumn 396, Issue 1-2, 2013, Pages 44-55

  Weeraratne, Dohan K ^a   Lofgren, James ^a   Dinnogen, Steve ^a   Swanson, Steven J ^a   Zhong, Zhandong Don ^a  

^a AMGEN INC   (United States)

Author keywords

AMG 386; Anti drug antibody; Biacore ; Immunogenicity; Soluble drug target interference; Trebananib

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CROSS REACTING ANTIBODY; DRUG ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; TREBANANIB;

ANGIOGENESIS; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; BIOSENSOR; CANCER PATIENT; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG SENSITIVITY; DRUG TOLERANCE; FALSE POSITIVE RESULT; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE;

ADA; AFFINITY CONSTANT; AMG 386; ANG1; ANG2; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTI-DRUG ANTIBODY; ASSOCIATION RATE CONSTANT; BIACORE®; DISSOCIATION RATE CONSTANT; ECL; ELECTROCHEMILUMINESCENCE; IG; IMMUNOGENICITY; IMMUNOGLOBULIN; K(A); K(D); MESO SCALE DISCOVERY; MSD; RESPONSE UNIT; RU; S/N; SIGNAL-TO-NOISE RATIO; SOLUBLE DRUG TARGET INTERFERENCE; SPR; SURFACE PLASMON RESONANCE; TREBANANIB;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIBODIES, ANTI-IDIOTYPIC; BIOSENSING TECHNIQUES; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUMINESCENCE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; RECOMBINANT FUSION PROTEINS; SURFACE PLASMON RESONANCE;

CAPRA HIRCUS;

EID: 84884355216     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.07.010     Document Type: Article

References (67)

1. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105:9.
2. Aalberse R.C., van der Gaag R., van Leeuwen J. Serologic aspects of IgG4 antibodies. J. Immunol. 1983, 130:722.
3. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 2009, 39:469.
4. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008, 20:431.
5. Anargyrou K., Terpos E., Vassilakopoulos T.P., Pouli A., Sachanas S., Tzenou T., Masouridis S., Christoulas D., Angelopoulou M.K., Dimitriadou E.M., Kalpadakis C., Tsionos K., Panayiotidis P., Dimopoulos M.A., Pangalis G.A., Kyrtsonis M.-C. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008, 93:451.
6. Augustin H.G., Koh G.Y., Thurston G., Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 2009, 10:165.
7. Barton W.A., Tzvetkova-Robev D., Miranda E.P., Kolev M.V., Rajashankar K.R., Himanen J.P., Nikolov D.B. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat. Struct. Mol. Biol. 2006, 13:524.
8. Bourdage J.S., Cook C.A., Farrington D.L., Chain J.S., Konrad R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 2007, 327:10.
9. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M.A., Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 1999, 155:1967.
10. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417.
11. Carrasco-Triguero M., Mahood C., Milojic-Blair M., Amaya C., Ruppel J., Hong K., Yi J.H., Kaur S. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis 2012, 4:2013.
12. Committee for Medicinal Product for Human Use Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Doc. Ref. EMEA/CHMP/BMWP/14327/2006, London, 2007 2007.
13. Coxon A., Bready J., Min H., Kaufman S., Leal J., Yu D., Lee T.A., Sun J.R., Estrada J., Bolon B., McCabe J., Wang L., Rex K., Caenepeel S., Hughes P., Cordover D., Kim H., Han S.J., Michaels M.L., Hsu E., Shimamoto G., Cattley R., Hurh E., Nguyen L., Wang S.X., Ndifor A., Hayward I.J., Falcon B.L., McDonald D.M., Li L., Boone T., Kendall R., Radinsky R., Oliner J.D. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol. Cancer Ther. 2010, 9:2641.
14. Davis S., Papadopoulos N., Aldrich T.H., Maisonpierre P.C., Huang T., Kovac L., Xu A., Leidich R., Radziejewska E., Rafique A., Goldberg J., Jain V., Bailey K., Karow M., Fandl J., Samuelsson S.J., Ioffe E., Rudge J.S., Daly T.J., Radziejewski C., Yancopoulos G.D. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 2003, 10:38.
15. De Palma M., Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res. 2011, 17:5226.
16. Detjen K.M., Rieke S., Deters A., Schulz P., Rexin A., Vollmer S., Hauff P., Wiedenmann B., Pavel M., Scholz A. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin. Cancer Res. 2010, 16:420.
17. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20:4368.
18. Eatock M., Tebbutt N., Bampton C.L., Strickland A., Valladares-Ayerbes M., Swieboda-Sadlej A., Van Cutsem E., Nanayakkara N., Sun Y.-N., Zhong D., Bass M.B., Adewoye A.H., Bodoky G. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann. Oncol. 2013, 24:710.
19. Etoh T., Inoue H., Tanaka S., Barnard G.F., Kitano S., Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001, 61:2145.
20. Fidler I.J., Kerbel R.S., Ellis L.M. Biology of cancer: angiogenesis. Principles and Practice of Oncology 2001, 137. Lippincott-Raven Publisher, Philadelphia, PA. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
21. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27.
22. Hart M.H., de Vrieze H., Wouters D., Wolbink G.-J., Killestein J., de Groot E.R., Aarden L.A., Rispens T. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods 2011, 372:196.
23. Herbst R.S., Hong D., Chap L., Kurzrock R., Jackson E., Silverman J.M., Rasmussen E., Sun Y.N., Zhong D., Hwang Y.C., Evelhoch J.L., Oliner J.D., Le N., Rosen L.S. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 2009, 27:3557.
24. Jawa V., Hokom M., Hu Z., El-Abaadi N., Zhuang Y., Berger D., Gupta S., Swanson S.J., Chirmule N. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann. Hematol. 2010, 89(Suppl. 1):S75.
25. Karlan B.Y., Oza A.M., Richardson G.E., Provencher D.M., Hansen V.L., Buck M., Chambers S.K., Ghatage P., Pippitt C.H., Brown J.V., Covens A., Nagarkar R.V., Davy M., Leath C.A., Nguyen H., Stepan D.E., Weinreich D.M., Tassoudji M., Sun Y.N., Vergote I.B. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol. 2012, 30:362.
26. Kim K.T., Choi H.H., Steinmetz M.O., Maco B., Kammerer R.A., Ahn S.Y., Kim H.Z., Lee G.M., Koh G.Y. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J. Biol. Chem. 2005, 280:20126.
27. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., Barrett Y.C., Devanarayan V., Gorovits B., Gupta S., Parish T., Quarmby V., Moxness M., Swanson S.J., Taniguchi G., Zuckerman L.A., Stebbins C.C., Mire-Sluis A. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
28. Labrijn A.F., Buijsse A.O., van den Bremer E.T.J., Verwilligen A.Y.W., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G.J., Parren P.W.H.I. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 2009, 27:767.
29. Leek R.D. The prognostic role of angiogenesis in breast cancer. Anticancer Res. 2001, 21:4325.
30. Liang M., Klakamp S.L., Funelas C., Lu H., Lam B., Herl C., Umble A., Drake A.W., Pak M., Ageyeva N., Pasumarthi R., Roskos L.K. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 2007, 5:655.
31. Lofgren J.A., Dhandapani S., Pennucci J.J., Abbott C.M., Mytych D.T., Kaliyaperumal A., Swanson S.J., Mullenix M.C. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 2007, 178:7467.
32. Mehta R., Kyshtoobayeva A., Kurosaki T., Small E.J., Kim H., Stroup R., McLaren C.E., Li K.T., Fruehauf J.P. Independent association of angiogenesis index with outcome in prostate cancer. Clin. Cancer Res. 2001, 7:81.
33. Mikulskis A., Yeung D., Subramanyam M., Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 2011, 365:38.
34. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1.
35. Mita A.C., Takimoto C.H., Mita M., Tolcher A., Sankhala K., Sarantopoulos J., Valdivieso M., Wood L., Rasmussen E., Sun Y.N., Zhong Z.D., Bass M.B., Le N., LoRusso P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin. Cancer Res. 2010, 16:3044.
36. Moxness M., Tatarewicz S., Weeraratne D., Murakami N., Wullner D., Mytych D., Jawa V., Koren E., Swanson S.J. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 2005, 51:1983.
37. Mytych D.T., La S., Barger T., Ferbas J., Swanson S.J. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J. Pharm. Biomed. Anal. 2009, 49:415.
38. Mytych D.T., Barger T.E., King C., Grauer S., Haldankar R., Hsu E., Wu M.M., Shiwalkar M., Sanchez S., Kuck A., Civoli F., Sun J., Swanson S.J. Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing. J. Immunol. Methods 2012, 382:129.
39. Neubert H., Grace C., Rumpel K., James I. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal. Chem. 2008, 80:6907.
40. Niedzwiecki S., Stepien T., Kopec K., Kuzdak K., Komorowski J., Krupinski R., Stepien H. Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 2006, 36:291.
41. Oliner J., Min H., Leal J., Yu D., Rao S., You E., Tang X., Kim H., Meyer S., Han S.J., Hawkins N., Rosenfeld R., Davy E., Graham K., Jacobsen F., Stevenson S., Ho J., Chen Q., Hartmann T., Michaels M., Kelley M., Li L., Sitney K., Martin F., Sun J.R., Zhang N., Lu J., Estrada J., Kumar R., Coxon A., Kaufman S., Pretorius J., Scully S., Cattley R., Payton M., Coats S., Nguyen L., Desilva B., Ndifor A., Hayward I., Radinsky R., Boone T., Kendall R. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507.
42. Papamichael D. Prognostic role of angiogenesis in colorectal cancer. Anticancer Res. 2001, 21:4349.
43. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 2005, 304:189.
44. Peeters M., Strickland A.H., Lichinitser M., Suresh A.V., Manikhas G., Shapiro J., Rogowski W., Huang X., Wu B., Warner D., Jain R., Tebbutt N.C. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br. J. Cancer 2013, 108:503.
45. Peters K.G., Kontos C.D., Lin P.C., Wong A.L., Rao P., Huang L., Dewhirst M.W., Sankar S. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog. Horm. Res. 2004, 59:51.
46. Reinmuth N., Parikh A.A., Ahmad S.A., Liu W., Stoeltzing O., Fan F., Takeda A., Akagi M., Ellis L.M. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc. Res. Tech. 2003, 60:199.
47. Rini B., Szczylik C., Tannir N.M., Koralewski P., Tomczak P., Deptala A., Dirix L.Y., Fishman M., Ramlau R., Ravaud A., Rogowski W., Kracht K., Sun Y.N., Bass M.B., Puhlmann M., Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012, 118:6152.
48. Sanchez S., Barger T., Zhou L., Hale M., Mytych D., Gupta S., Swanson S.J., Civoli F. Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. J. Pharm. Biomed. Anal. 2011, 55:1265.
49. Scappaticci F.A. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002, 20:3906.
50. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005, 118:771.
51. Sfiligoi C., de Luca A., Cascone I., Sorbello V., Fuso L., Ponzone R., Biglia N., Audero E., Arisio R., Bussolino F., Sismondi P., De Bortoli M. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer 2003, 103:466.
52. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
53. Shim W.S., Ho I.A., Wong P.E. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol. Cancer Res. 2007, 5:655.
54. Sickert D., Kroeger K., Zickler C., Chokote E., Winkler B., Grenet J.M., Legay F., Zaar A. Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. J. Immunol. Methods 2008, 334:29.
55. Sie M., Wagemakers M., Molema G., Mooij J.J., de Bont E.S., den Dunnen W.F. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J. Neurosurg. 2009, 110:147.
56. Smith H.W., Butterfield A., Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regul. Toxicol. Pharmacol. 2007, 49:230.
57. Spengler M., Adler M., Jonas A., Niemeyer C.M. Immuno-PCR assays for immunogenicity testing. Biochem. Biophys. Res. Commun. 2009, 387:278.
58. Swanson S.J. New technologies for the detection of antibodies to therapeutic proteins. New Technologies for the Detection of Antibodies to Therapeutic Proteins 2003, vol. 112:127. Karger, Basel.
59. Swanson S.J. Immunogenicity issues in drug development. J. Immunotoxicol. 2006, 3:165.
60. Swanson S.J., Ferbas J., Mayeux P., Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin. Pract. 2004, 96:c88.
61. US Food and Drug Administration Guidance for industry: assay development for immunogenicity testing of therapeutic proteins (draft guidance). Published as a Notice in the Federal Register: 74 Fed. Reg. 63758, December 4, 2009 2009, (Docket No. FDA-2009-D-0539).
62. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods 2010, 362:82.
63. Wang H.-L., Deng C.-S., Lin J., Pan J.-Y., Zou Z.-Y., Zhou X.-Y. Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma. Tohoku J. Exp. Med. 2007, 213:33.
64. Wang Y.M., Fang L., Zhou L., Wang J., Ahn H.Y. A survey of applications of biological products for drug interference of immunogenicity assays. Pharm. Res. 2012, 29:3384.
65. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242.
66. Yu Y., Varughese J., Brown L.F., Mulliken J.B., Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin 1, and dysregulated angiopoietin 2 expression in hemangioma derived endothelial cells. Am. J. Pathol. 2001, 159:2271.
67. Zhong Z.D., Dinnogen S., Hokom M., Ray C., Weinreich D., Swanson S.J., Chirmule N. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 2010, 355:21.